Aspira Women's Health enters collaboration with Cleveland Clinic for AI-powered diagnostics

Aspira Women's Health Inc.

Partnering fee of $125,000; $50,000 due within 30 days, then $25,000 on each of first three anniversaries.
Collaboration focuses on biomarker discovery, AI-driven modeling, and clinical validation for women's health diagnostics.
Joint leadership: Dr. Kevin Elias (Cleveland Clinic) and Dr. Todd Pappas (Aspira) will lead multidisciplinary teams.
Initial five-year term; may be extended by mutual agreement; either party can terminate with 60 days' notice.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aspira Women's Health Inc. entered into Master Collaboration and License Agreement with Cleveland Clinic Foundation valued at Partnering fee of $125,000 total, payable $50,000 within 30 days, then $25,000 on first, second, and (effective 2026-05-20).

Action: entry
Agreement: collaboration
Counterparty: Cleveland Clinic Foundation
Value: Partnering fee of $125,000 total, payable $50,000 within 30 days, then $25,000 on first, second, and
Effective: 2026-05-20

Exact text from the filing

On May 20, 2026, Aspira Women’s Health Inc. (“Aspira”) announced that it had entered into a Master Collaboration and License Agreement (the “Agreement”) with Cleveland Clinic Foundation (“CCF”), a non-profit educational, research and health care institution.

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.